The estimated Net Worth of Jason Campagna is at least $324 Тысяча dollars as of 18 August 2020. Jason Campagna owns over 1,192 units of Intercept Pharmaceuticals Inc stock worth over $166,782 and over the last 5 years he sold ICPT stock worth over $157,674. In addition, he makes $0 as Chief Medical Officer at Intercept Pharmaceuticals Inc.
Jason has made over 3 trades of the Intercept Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,192 units of ICPT stock worth $56,548 on 18 August 2020.
The largest trade he's ever made was selling 1,192 units of Intercept Pharmaceuticals Inc stock on 18 August 2020 worth over $56,548. On average, Jason trades about 139 units every 16 days since 2019. As of 18 August 2020 he still owns at least 8,778 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Jason Campagna stock trades at the bottom of the page.
Dr. Jason Campagna M.D., Ph.D. serves as Chief Medical Officer of the Company. Dr. Campagna has over 15 years of leadership experience in the healthcare industry, including his role as Senior Vice President and NASH Program Leader at Intercept since 2016. Prior to Intercept, Dr. Campagna held a number of roles of increasing responsibility at The Medicines Company from 2010 to 2016, including most recently as Senior Vice President and Health Science Lead of Surgery and Perioperative Care. Earlier in his career Dr. Campagna served as the Chief Medical Quality Officer at Cottage Health System, held faculty appointments at the University of Pennsylvania and Harvard Medical School and was a Fellow at the Kennedy Institute of Ethics at Georgetown University. Dr. Campagna also served as Managing Director of Profibrix B.V., following its acquisition by The Medicines Company in 2013, and as a Director of Annovation Biopharma, Inc. prior to its acquisition by The Medicines Company in 2015. Presently, Dr. Campagna serves on the Steering Committee of the Wallace H. Coulter Center for Translational Research at the University of Miami Miller School of Medicine.
Jason Campagna is 50, he's been the Chief Medical Officer of Intercept Pharmaceuticals Inc since 2019. There are 20 older and 3 younger executives at Intercept Pharmaceuticals Inc. The oldest executive at Intercept Pharmaceuticals Inc is Keith Gottesdiener, 66, who is the Independent Director.
Jason's mailing address filed with the SEC is C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK, NY, 10001.
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein и Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include: